United Therapeutics Corporation - Asset Resilience Ratio
United Therapeutics Corporation (UTHR) has an Asset Resilience Ratio of 22.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of United Therapeutics Corporation for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how United Therapeutics Corporation's Asset Resilience Ratio has changed over time. See UTHR net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down United Therapeutics Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see UTHR company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.63 Billion | 22.19% |
| Total Liquid Assets | $1.63 Billion | 22.19% |
Asset Resilience Insights
- Good Liquidity Position: United Therapeutics Corporation maintains a healthy 22.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
United Therapeutics Corporation Industry Peers by Asset Resilience Ratio
Compare United Therapeutics Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117 |
Drug Manufacturers - Specialty & Generic | 3.51% |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566 |
Drug Manufacturers - Specialty & Generic | 5.72% |
Annual Asset Resilience Ratio for United Therapeutics Corporation (1999–2024)
The table below shows the annual Asset Resilience Ratio data for United Therapeutics Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.32% | $1.57 Billion | $7.36 Billion | -3.61pp |
| 2023-12-31 | 24.93% | $1.79 Billion | $7.17 Billion | -6.14pp |
| 2022-12-31 | 31.06% | $1.88 Billion | $6.04 Billion | +11.02pp |
| 2021-12-31 | 20.04% | $1.04 Billion | $5.17 Billion | -3.71pp |
| 2020-12-31 | 23.76% | $1.10 Billion | $4.62 Billion | +4.65pp |
| 2019-12-31 | 19.10% | $747.50 Million | $3.91 Billion | -2.85pp |
| 2018-12-31 | 21.96% | $746.70 Million | $3.40 Billion | +14.23pp |
| 2017-12-31 | 7.72% | $222.30 Million | $2.88 Billion | +6.52pp |
| 2016-12-31 | 1.20% | $27.80 Million | $2.33 Billion | -4.39pp |
| 2015-12-31 | 5.58% | $122.00 Million | $2.18 Billion | -10.22pp |
| 2014-12-31 | 15.81% | $297.84 Million | $1.88 Billion | -3.82pp |
| 2013-12-31 | 19.62% | $409.64 Million | $2.09 Billion | -0.37pp |
| 2012-12-31 | 19.99% | $325.18 Million | $1.63 Billion | +4.13pp |
| 2011-12-31 | 15.86% | $240.80 Million | $1.52 Billion | -10.33pp |
| 2010-12-31 | 26.19% | $374.92 Million | $1.43 Billion | +13.91pp |
| 2009-12-31 | 12.28% | $129.14 Million | $1.05 Billion | +0.05pp |
| 2008-12-31 | 12.23% | $106.60 Million | $871.32 Million | -13.44pp |
| 2007-12-31 | 25.68% | $150.73 Million | $587.02 Million | -2.88pp |
| 2006-12-31 | 28.56% | $136.68 Million | $478.55 Million | +9.24pp |
| 2005-12-31 | 19.32% | $56.30 Million | $291.41 Million | +19.22pp |
| 2004-12-31 | 0.10% | $200.00K | $207.16 Million | -17.07pp |
| 2002-12-31 | 17.16% | $31.68 Million | $184.57 Million | +2.23pp |
| 2001-12-31 | 14.93% | $31.68 Million | $212.12 Million | +9.15pp |
| 2000-12-31 | 5.78% | $14.48 Million | $250.64 Million | -49.81pp |
| 1999-12-31 | 55.59% | $33.30 Million | $59.90 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more